New feature: Quickly check share performance and dividends
Our new Share Checker feature lets you quickly check share performance and dividends! It works for managed funds and ETFs too.
We realised many of you like to keep a watchlist or "dream" portfolio in Sharesight. We do too. We've got a Berkshire Hathaway portfolio and a Tech All-Stars portfolio. Amazing what a little hindsight can do for your total return.
On the other hand, if you simply wanted to check a company's performance quickly or verify that you've selected the correct security, previously you had to add the holding to your portfolio by going to the trouble of creating a (fictitious) buy transaction.
Now with the Share Checker you can map the value of $1k invested in mere seconds without having to add phoney data to your portfolio. On the Portfolio Overview page, click the Share Checker button next to the Add Holding button. Then enter your data range, market, and code/name.
On an overlay, you'll see a hypothetical $1,000 investment. Further down the page, you'll see our familiar total return components and then several tabs corresponding to dividends, corporate actions, and news.
The Trades & Adjustments tab works out retrospectively how many units (rounded to the nearest whole unit) you would have needed to buy to get close to the initial investment of $1,000. Our total return calculation works out the difference between that initial $1,000 and today's value.
We hope you find this feature as handy as we do!
FURTHER READING

See what’s inside your ETFs with Sharesight’s exposure report
See inside your ETFs and get the full picture of your investment portfolio's composition with Sharesight's exposure report.

How KmacD Financial streamlines reporting and saves time with Sharesight
We talk to financial planning firm KmacD Financial about how the Sharesight-AdviserLogic integration helps them save time and streamline client reporting.

Sharesight product updates – November 2023
The focus over the past month has been on implementing additional feature ideas relating to our new (beta) exposure report.